{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:06:10Z","timestamp":1789679170113,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ypmed.2026.108663","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:24:00Z","timestamp":1788949440000},"page":"108663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human behavioral pharmacology of cannabis: Insights on cannabis use disorder"],"prefix":"10.1016","author":[{"given":"Margaret","family":"Haney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Arout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret F.","family":"Bedillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2026.108663_bb0005","series-title":"Cannabis Use Disorder","first-page":"75","article-title":"Human laboratory models of cannabis use disorder","author":"Arout","year":"2019"},{"issue":"5","key":"10.1016\/j.ypmed.2026.108663_bb0010","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1021\/acschemneuro.8b00651","article-title":"Dark classics in chemical neuroscience: \u03949-Tetrahydrocannabinol","volume":"10","author":"Banister","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ypmed.2026.108663_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/7854_2025_598","article-title":"Pharmacotherapy for Cannabis use disorder: preclinical and clinical models","volume":"76","author":"Bedillion","year":"2026","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.ypmed.2026.108663_bb9038","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/npp.2017.212","article-title":"The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal","volume":"43","author":"Brezing","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.ypmed.2026.108663_bb0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17512433.2020.1721281","article-title":"The \u201centourage effect\u201d or \u201cHodge-podge hashish\u201d: the questionable rebranding, marketing, and expectations of cannabis polypharmacy","volume":"13","author":"Cogan","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ypmed.2026.108663_bb0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1369-1600.2007.00095.x","article-title":"Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor","volume":"13","author":"Cooper","year":"2008","journal-title":"Addict. Biol."},{"issue":"3","key":"10.1016\/j.ypmed.2026.108663_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2009.01.023","article-title":"Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts","volume":"103","author":"Cooper","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.ypmed.2026.108663_bb0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-010-1875-y","article-title":"Opioid antagonism enhances marijuana\u2019s effects in heavy marijuana smokers","volume":"211","author":"Cooper","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ypmed.2026.108663_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.drugalcdep.2013.12.013","article-title":"Investigation of sex-dependent effects of cannabis in daily cannabis smokers","volume":"136","author":"Cooper","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.ypmed.2026.108663_bb0045","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/npp.2013.97","article-title":"Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers","volume":"38","author":"Cooper","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.ypmed.2026.108663_bb0050","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41386-018-0011-2","article-title":"Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability","volume":"43","author":"Cooper","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.ypmed.2026.108663_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66879-0","article-title":"Acute effects of cannabigerol on anxiety, stress, and mood: A double-blind, placebo-controlled, crossover, field trial","volume":"14","author":"Cuttler","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ypmed.2026.108663_bb0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","article-title":"Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States","volume":"79","author":"ElSohly","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ypmed.2026.108663_bb0065","first-page":"1","article-title":"Phytochemistry of cannabis sativa L","volume":"103","author":"ElSohly","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"issue":"1","key":"10.1016\/j.ypmed.2026.108663_bb0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0376-8716(87)90079-2","article-title":"Effects of smoked marijuana on social interaction in small groups","volume":"20","author":"Foltin","year":"1987","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.ypmed.2026.108663_bb0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11920-005-0036-1","article-title":"The marijuana withdrawal syndrome: diagnosis and treatment","volume":"7","author":"Haney","year":"2005","journal-title":"Curr. Psychiatry Rep."},{"issue":"6","key":"10.1016\/j.ypmed.2026.108663_bb0080","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.npp.1301243","article-title":"Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers","volume":"32","author":"Haney","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.ypmed.2026.108663_bb0085","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamapsychiatry.2020.1032","article-title":"Perspectives on cannabis research-barriers and recommendations","volume":"77","author":"Haney","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.ypmed.2026.108663_bb9039","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","article-title":"Controversies in translational research: drug self-administration","volume":"199","author":"Haney","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.ypmed.2026.108663_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.ypmed.2026.108663_bb0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biopsych.2012.07.028","article-title":"Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status","volume":"73","author":"Haney","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.ypmed.2026.108663_bb0100","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2015.108","article-title":"Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers","volume":"40","author":"Haney","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.ypmed.2026.108663_bb0105","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.ypmed.2026.108663_bb0110","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41591-023-02381-w","article-title":"Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: Phase 1 and phase 2a randomized trials","volume":"29","author":"Haney","year":"2023","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ypmed.2026.108663_bb0115","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"issue":"4","key":"10.1016\/j.ypmed.2026.108663_bb0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.ypmed.2026.108663_bb0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamapsychiatry.2024.4145","article-title":"Association of state cannabis legalization with cannabis use disorder and cannabis poisoning","volume":"82","author":"Jayawardhana","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.ypmed.2026.108663_bb0130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1089\/can.2021.0185","article-title":"The relationship between circulating endogenous cannabinoids and the effects of smoked cannabis","volume":"8","author":"Kearney-Ramos","year":"2023","journal-title":"Cannabis & Cannabinoid Research"},{"issue":"1","key":"10.1016\/j.ypmed.2026.108663_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","article-title":"Drug addiction: Hyperkatifeia\/negative reinforcement as a framework for medications development","volume":"73","author":"Koob","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ypmed.2026.108663_bb0140","article-title":"In the weeds: A comprehensive review of cannabis; its chemical complexity, biosynthesis, and healing abilities","volume":"13","author":"Laaboudi","year":"2024","journal-title":"Toxicol. Rep."},{"issue":"7","key":"10.1016\/j.ypmed.2026.108663_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13301","article-title":"Sex differences in the subjective and reinforcing effects of smoked cannabis","volume":"28","author":"Lake","year":"2023","journal-title":"Addict. Biol."},{"key":"10.1016\/j.ypmed.2026.108663_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.70284","article-title":"Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial","author":"Lavender","year":"2026","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.ypmed.2026.108663_bb0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2026.108663_bb0160","series-title":"Cannabis policy impacts public health and health equity","author":"National Academies of Sciences, Engineering, and Medicine","year":"2024"},{"issue":"4","key":"10.1016\/j.ypmed.2026.108663_bb0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1037\/a0033661","article-title":"Marijuana\u2019s dose-dependent effects in daily marijuana smokers","volume":"21","author":"Ramesh","year":"2013","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ypmed.2026.108663_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised \u0394 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ypmed.2026.108663_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111267","article-title":"Vaporized D-limonene selectively mitigates the acute anxiogenic effects of \u03949-tetrahydrocannabinol in healthy adults who intermittently use cannabis","volume":"257","author":"Spindle","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2026.108663_bb0180","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.psychres.2017.07.070","article-title":"Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study","volume":"257","author":"Vadhan","year":"2017","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.ypmed.2026.108663_bb0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09540261.2018.1491107","article-title":"The cannabis conundrum: steering policy and medicine with insufficient data","volume":"30","author":"Vandrey","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"issue":"5","key":"10.1016\/j.ypmed.2026.108663_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103571","article-title":"Is there a continued need for behavioral pharmacology in the discovery and development of medicines?","volume":"392","author":"Witkin","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743526001696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743526001696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:55:49Z","timestamp":1789678549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743526001696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0091743526001696"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2026.108663","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human behavioral pharmacology of cannabis: Insights on cannabis use disorder","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2026.108663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108663"}}